title: Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
abstract: The magnitude and durability of immune responses induced by replication-defective adenovirus serotype 5 (ADV5) vector-based vaccines were evaluated in the simian-human immunodeficiency virus/rhesus monkey model. A single inoculation of recombinant ADV5 vector constructs induced cellular and humoral immunity, but the rapid generation of neutralizing anti-Ad5 antibodies limited the immunity induced by repeated vector administration. The magnitude and durability of the immune responses elicited by these vaccines were greater when they were delivered as boosting immunogens in plasmid DNA-primed monkeys than when they were used as single-modality immunogens. Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection.
authors.affiliation: Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P. O. Box 15732, Boston, MA 02215, USA.
authors.forename: Sampa
authors.initials: S
authors.lastname: Santra
authors.forename: Michael S
authors.initials: MS
authors.lastname: Seaman
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.forename: Dan H
authors.initials: DH
authors.lastname: Barouch
authors.forename: Carol I
authors.initials: CI
authors.lastname: Lord
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Lifton
authors.forename: Darci A
authors.initials: DA
authors.lastname: Gorgone
authors.forename: Kristin R
authors.initials: KR
authors.lastname: Beaudry
authors.forename: Krisha
authors.initials: K
authors.lastname: Svehla
authors.forename: Brent
authors.initials: B
authors.lastname: Welcher
authors.forename: Bimal K
authors.initials: BK
authors.lastname: Chakrabarti
authors.forename: Yue
authors.initials: Y
authors.lastname: Huang
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Yang
authors.forename: John R
authors.initials: JR
authors.lastname: Mascola
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Nabel
authors.forename: Norman L
authors.initials: NL
authors.lastname: Letvin
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D017498:Adenovirus E1 Proteins / Q000235:genetics; D017503:Adenovirus E3 Proteins / Q000235:genetics; D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D004353:Drug Evaluation, Preclinical; D017353:Gene Deletion; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D007117:Immunization, Secondary; D007273:Injections, Intramuscular; D008253:Macaca mulatta; D009500:Neutralization Tests; D010957:Plasmids / Q000235:genetics; D016097:Simian Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D017498:Adenovirus E1 Proteins; D017503:Adenovirus E3 Proteins; D000914:Antibodies, Viral; D015483:HIV Antibodies; D019444:Vaccines, DNA; D014765:Viral Vaccines